Crisis Looms in Antibiotics as Drug Makers Go Bankrupt

First Big Pharma fled the field, and now start-ups are going belly up, threatening to stifle the development of new drugs.

At a time when germs are growing more resistant to common antibiotics, many companies that are developing new versions of the drugs are hemorrhaging money and going out of business, gravely undermining efforts to contain the spread of deadly, drug-resistant bacteria.

Antibiotic start-ups like Achaogen and Aradigm have gone belly up in recent months, pharmaceutical behemoths like Novartis and Allergan have abandoned the sector and many of the remaining American antibiotic companies are teetering toward insolvency. One of the biggest developers of antibiotics, Melinta Therapeutics, recently warned regulators it was running out of cash…

The New York Times

Crisis Looms in Antibiotics as Drug Makers Go Bankrupt

Andrew Jacobs

December 25, 2019

First Big Pharma fled the field, and now start-ups are going belly up, threatening to stifle the development of new drugs.

More

Wall Street Journal

The World Needs New Antibiotics. The Problem Is, No One Can Make Them Profitably.

Pharmaceutical Technology

Fighting AMR with a value and subscription model

Fierce Biotech

Scientists use AI to find new antibiotics, but can they climb out of the ‘valley of death’ to the clinic?

PHARMAVOICE

‘The Last of Us’ might be fiction, but fungi are a looming threat

Sign up for the latest on fighting AMR